Effect of Adjuvant Chemotherapy after Complete Resection for Pathologic Stage IB Lung Adenocarcinoma in High-Risk Patients as Defined by a New Recurrence Risk Scoring Model
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose We conducted a retrospective analysis to determine if adjuvant chemotherapy prolongs overall survival in patients with pathologic stage IB lung adenocarcinoma who had undergone complete resection and were defined as high-risk by a newly developed recurrence risk scoring model. Materials and Methods Patients who underwent curative resection for stage IB lung adenocarcinoma were analyzed with a newly developed recurrence risk scoring model and divided into a low-risk group and a high-risk group. The patients in the high-risk group were retrospectively divided into two groups based on whether they underwent adjuvant chemotherapy or observation. Recurrence- free survival and overall survival were compared between these two groups. Results A total of 328 patients who underwent curative resection between 2000 and 2009 were included in this study, of whom 110 (34%) received adjuvant chemotherapy and 218 (67%) underwent observation without additional treatment. According to our risk model, 167 patients (51%) were high-risk and 161 (49%) were low-risk. The 5-year recurrence-free survival rates and overall survival were 84.4% and 91.5% in low-risk patients and 53.9% and 74.7% in high-risk patients (p < 0.001). In high-risk patients, the 5-year overall survival rates were 77% among patients who underwent observation and 87% among those who underwent adjuvant chemotherapy (p=0.019). Conclusion Adjuvant chemotherapy prolonged overall survival among high-risk patients who had undergone complete resection for stage IB lung adenocarcinoma.
Abstract
Purpose We conducted a retrospective analysis to determine if adjuvant chemotherapy prolongs overall survival in patients with pathologic stage IB lung adenocarcinoma who had undergone complete resection and were defined as high-risk by a newly developed recurrence risk scoring model. Materials and Methods Patients who underwent curative resection for stage IB lung adenocarcinoma were analyzed with a newly developed recurrence risk scoring model and divided into a low-risk group and a high-risk group. The patients in the high-risk group were retrospectively divided into two groups based on whether they underwent adjuvant chemotherapy or observation. Recurrence- free survival and overall survival were compared between these two groups. Results A total of 328 patients who underwent curative resection between 2000 and 2009 were included in this study, of whom 110 (34%) received adjuvant chemotherapy and 218 (67%) underwent observation without additional treatment. According to our risk model, 167 patients (51%) were high-risk and 161 (49%) were low-risk. The 5-year recurrence-free survival rates and overall survival were 84.4% and 91.5% in low-risk patients and 53.9% and 74.7% in high-risk patients (p < 0.001). In high-risk patients, the 5-year overall survival rates were 77% among patients who underwent observation and 87% among those who underwent adjuvant chemotherapy (p=0.019). Conclusion Adjuvant chemotherapy prolonged overall survival among high-risk patients who had undergone complete resection for stage IB lung adenocarcinoma.
참고문헌 (14)
- Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)
- Goldstraw P, "The IASLC Lung Cancer Staging Project : proposals for the revision of the TNM stage groupings in the forthcoming(seventh)edition of the TNM Classification of malignant tumours", J Thorac Oncol, 2, pp.706~714 (2007)
- Arriagada R, "Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer", N Engl J Med, 350, pp.351~360 (2004)
- ) : a randomised controlled trial, "Lancet Oncol", 2006, 719~727
- Winton T, "Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer", N Engl J Med, 352, pp.2589~2597 (2005)
- Strauss GM, "Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer : CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups", J Clin Oncol, 26, pp.5043~5051 (2008)
- Carlson RW, "International adaptations of NCCN clinical practice guidelines in oncology", J Natl Compr Canc Netw, 12, pp.643~648 (2014)
- Yang HC, "Recurrence risk-scoring model for stage I adenocarcinoma of the lung", Ann Surg Oncol, 22, pp.4089~4097 (2015)
- Martini N, "Multiple primary lung cancers", J Thorac Cardiovascular Surg, 70, pp.606~612 (1975)
- Ramnath N, "Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed:American College of Chest Physicians evidence-based clinical practice guidelines", Chest, 143(5 Suppl), pp.314S~340S (2013)
- Scagliotti GV, "Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer", J Natl Cancer Inst, 95, pp.1453~1461 (2003)
- Shimizu K, "Visceral pleural invasion is an invasive and aggressive indicator of non-small cell lung cancer", J Thorac Cardiovasc Surg, 130, pp.160~165 (2005)
- Mizuno T, "Identification of a low risk subgroup of stage IB lung adenocarcinoma patients", Lung Cancer, 62, pp.302~308 (2008)
- Nitadori J, "Visceral pleural invasion does not affect recurrence or overall survival among patients with lung adenocarcinoma ≤ 2 cm : a proposal to reclassify T1 lung adenocarcinoma", Chest, 144, pp.1622~1631 (2013)